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Abstract
The non-histone chromatin binding protein high mobility group AT-hook 2 (HMGA2) is expressed in stem cells and
many cancer cells, including tumor initiating cells, but not translated in normal human somatic cells. The presence
of HMGA2 is correlated with advanced neoplastic disease and poor prognosis for patients. We had previously
demonstrated a role of HMGA2 in DNA repair pathways. In the present study, we employed different human tumor
cell models with endogenous and exogenous expression of HMGA2 and show that upon DNA damage, the pres-
ence of HMGA2 caused an increased and sustained phosphorylation of the ataxia telangiectasia and Rad3-related
kinase (ATR) and its downstream target checkpoint kinase 1 (CHK1). The presence of activated pCHK1Ser296
coincided with prolonged G2/M block and increased tumor cell survival, which was enhanced further in the pres-
ence of HMGA2. Our study, thus, identifies a novel relationship between the ATR-CHK1 DNA damage response
pathway and HMGA2, which may support the DNA repair function of HMGA2 in cancer cells. Furthermore, our data
provide a rationale for the use of inhibitors to ATR or CHK1 and HMGA2 in the treatment of HMGA2-positive human
cancer cells.
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Introduction
The small high mobility group AT-hook (HMGA) non-histone
chromatin binding proteins HMGA1 and HMGA2 are composed
of an acidic C-terminal tail and three separate N-terminal lysine–
and arginine-rich AT-hook domains, which facilitate binding to
the minor groove of short stretches of AT-rich DNA [1]. HMGA2
is expressed in embryonic stem (ES) cells, during embryogenesis, in
some fetal tissues, and in some cancer cells. The protein is usually
not detectable in normal adult somatic cells [2]. Phenotypically,
HMGA1/2-positive cells display improved resistance to therapies
that introduce chemical modifications of DNA bases, such as oxida-
tion and alkylation [3–5]. HMGA2 knockout mice exhibit a pygmy
phenotype with greatly reduced fat tissues, and male mice are infer-
tile [6,7]. By contrast, tissue-specific overexpression of full-length or
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ubiquitous expression of a truncated protein lacking the C-terminal
tail results in gigantism, lipomatosis, and mesenchymal tumors [8,9].
We showed recently that HMGA2 remains associated with chro-
matin throughout the cell cycle in pluripotent human ES cells and
that HMGA2 expression levels are further elevated during human
embryoid body formation [10]. Furthermore, HMGA2 seems to
be involved in the regulation of key human genes linked to mesen-
chymal cell lineage differentiation, adipogenesis, and human ES cell
proliferation control [11]. We also demonstrated that HMGA1 and
HMGA2 are linked to DNA base excision repair and this may have
important implications for genome stability in ES cells and during
early development and carcinogenesis [5].
Unique among DNA architectural chromatin binding factors, the
HMGA genes are considered proto-oncogenes. HMGA1/2 proteins
are consistently overexpressed in nearly all types of naturally occur-
ring cancers and are important for multiple cellular processes includ-
ing oncogenic transformation [12–15]. It has been recognized that
high HMGA1/2 protein levels are associated with increased malig-
nancy, metastatic potential, and poor clinical outcome [13,16–18].
HMGA2 expression is primarily regulated by the miRNAs let-7 and
miRNA-98 during oncogenic transformation [19,20], but the molec-
ular mechanisms linking let-7 and HMGA2 with chemoresistance in
cancer cells and cancer stem/initiating cells remain elusive [21].
Exposure of cells to DNA-damaging agents results in the activa-
tion of a signaling cascade aimed at arresting the cell cycle to repair
the DNA damage or trigger apoptosis. The ataxia telangiectasia
mutated (ATM) and ataxia telangiectasia and Rad3-related kinase
(ATR) are related phosphatidylinositol 3-kinase-related kinases with
important functions in the DNA damage response (DDR) pathways.
ATM and its downstream target checkpoint kinase 2 (CHK2) con-
stitute the main response to double-stranded DNA breakage [22].
The activation of the ATR and its downstream target CHK1 generally
occurs in response to UV and agents that inhibit DNA replication
forks [23–25]. ATR and CHK1 participate in the stabilization of forks,
repair of DNA damage, and the inhibition of late origin firing [26–29].
The interaction between ATR and the ATR-interacting protein is
essential for the phosphorylation of CHK1 and cells depleted of
CHK1 accumulatemultipleDNAbreaks and undergoP53-independent
apoptosis [30,31]. Recent evidence shows that the activated ATR-
CHK1 pathway in response to fork inhibition preferentially inhibits
the activation of new replication fork factories, defined as clusters of
one or more adjacent replication origins [32–34]. This strategy con-
serves replication capacity for already active replicon clusters where forks
are inhibited rather than engaging new replication factories, and this
minimizes the risk of apoptosis [35]. Although different DNA-damaging
agents can preferentially activate one of the two DDR signaling path-
ways [36], both ATM-CHK2– and ATR-CHK1–mediated DDRs
are required for cell survival [31].
ATM was recently shown to interact with and phosphorylate
HMGA2, and phosphorylated HMGA2 activated a positive feedback
loop by upregulating ATM expression [37]. In the present study, we
demonstrate a novel interaction between ATR-CHK1 and HMGA2
and provide evidence for a new cytoprotective role of HMGA2 by
sustaining ATR-CHK1 phosphorylation. In four different cancer cell
models used here, we show that the antiapoptotic activity of HMGA2
is mediated by activated pCHK1. Depletion of HMGA2, CHK1, or
both factors resulted in mitotic cell cycle arrest, increased number of
nuclear γ-H2AX foci, and caspase 3/7–mediated apoptosis with de-
creased resistance to the genotoxic agents methyl methane sulfonate
(MMS) and hydroxyurea (HU). Thus, our data provide first evidence
for an active role of HMGA2 in the ATR-CHK1 DDR pathway.
Materials and Methods
Cell Lines and Culture Conditions
We used established lung cancer A549-HMGA2 transfectants [5]
and generated stable transfectants of the undifferentiated thyroid
cancer cell line UTC8505 expressing human HMGA2 as described
previously [38]. Transfectants were cultured in DME-F12 medium
(Thermo Scientific, Ottawa, Ontario) plus 10% fetal calf serum
(FCS; Sigma, Oakville, Ontario) and 500 μg/ml geneticin (Life
Technologies, Burlington, Ontario). The fibrosarcoma cell line
HT1080 (C1) harboring a doxycycline-inducible shHMGA2 con-
struct was generated by standard lentiviral transduction using a
Tet-on shHMGA2 construct, pTRIPz-shHMGA2 (Origene, Rockville,
MD). Cells were grown in DME-F12 supplemented with 10% FCS
and 3 μg/ml puromycin (Sigma). Induction of shHMGA2was achieved
with 4 μg/ml doxycycline (Sigma) for 48 hours with repeated doses ev-
ery 24 hours and resulted in significant down-regulation of endogenous
HMGA2. Human rhabdomyosarcoma (RD) cells were propagated in
DME-F12/10% FCS. All cell lines were maintained in a humidified
incubator under 5% CO2 at 37°C.
Comet Assay
UTC8505 mock and HMGA2 transfectants (106 cells/ml) were
cultured in serum-free DME-F12 medium and comet assays were
performed as described earlier [5]. Images were obtained at 400-fold
magnification using a chroma filter at 385-nm excitation/450-nm
emission with a Z1 microscope (Zeiss, Jena, Germany). We used the
(http://www.autocomet.com/products_cometscore.php) Comet Score
Version 1.5 analysis software. DNA damage was quantified by the
Olive tail moment [39].
Induction and Recovery Time Kinetic Assays
Cells (105 cells/well) in six-well plates were grown overnight. For
induction time kinetics, DNA damage was induced by MMS treat-
ment for 2, 5, 10, 15, 20, and 30 minutes and protein extracts were
collected. For recovery time kinetics, cells were treated with MMS
for 30 minutes and washed thoroughly twice with 1× phosphate-
buffered saline (PBS) to remove MMS. Cells received fresh medium
and were allowed to recover from MMS damage for 0, 1, 2, 4, 6, and
24 hours before total protein extraction.
Immunoblot Analysis
Proteins were separated by sodium dodecyl sulfate–polyacrylamide
gel electrophoresis and blotted onto nitrocellulose membrane (VWR,
Mississauga, Ontario) followed by blocking with 5% skimmed milk
in 1× Tris-buffered saline and 0.1% Tween 20 (pH 7.6). Membranes
were incubated with the primary antibody overnight at 4°C in 5%
BSA containing 1× Tris-buffered saline and 0.1% Tween 20 followed
by the secondary antibody in blocking buffer for 1 hour at room tem-
perature and detection of bands with the ECL Kit (Pierce, Nepean,
Ontario). Primary rabbit polyclonal antibodies used were against
phospho-ATR (pATRSer428), phospho-CHK1 (pCHK1Ser296), phospho-
CHK2 (pCHK2Thr68), total ATR, total CHK1, and total CHK2
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(all from Cell Signaling Technology, Pickering, Ontario) and goat
HMGA2 antibody (Santa Cruz Biotechnology, Santa Cruz, CA).
Anti-rabbit IgG (Cell Signaling Technology) and rabbit anti-goat
IgG (Santa Cruz Biotechnology) conjugated with HRP were used as
secondary antibodies.
Immunofluorescence
The C1 human fibrosarcoma cells were cultured on glass slides
plus/minus doxycycline (4 μg/ml) for 48 hours to attain HMGA2+
and HMGA2low cells, respectively. Cells were treated with MMS
(Sigma) for 30 minutes and then washed twice with 1× PBS. After
Figure 1. Characterization of stable HMGA2 transfectants. (A) Representative immunoblot and (B) immunofluorescent images showing
nuclear presence of HMGA2 in two UTC8505-HMGA2 stable transfectants. (C) Immunofluorescence detection of the DNA damage
response marker γ-H2AX indicating MMS-induced DNA damage in UTC8505 cells. Green stain, HMGA2; red stain, γ-H2AX; blue stain,
nucleus. (D) Quantification of three independent comet assays of UTC8505-HMGA2 (clone 4) and mock (clone 2) transfectants upon
MMS-induced DNA damage is shown. MMS was effective in causing DNA damage, as shown by a markedly longer tail moment com-
pared to untreated cells. There was a significant reduction in tail moment upon MMS treatment in the presence of HMGA2, suggesting
increased DNA repair capability in UTC-HMGA2 transfectants compared to mock. (*P < .05).
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fixation with 3.7% formaldehyde, cells were blocked with 1% BSA
containing 0.1% Triton X-100 plus 5% serum. Incubation with the
goat anti-HMGA2 (Santa Cruz Biotechnology) and mouse anti–γ-
H2AX (Millipore, Billerica, MA) in blocking solution was done at
4°C overnight before incubation with fluorescein isothiocyanate–
conjugated swine anti-goat (DAKO, Burlington, Ontario) and
Alexa Fluor 594–conjugated rabbit anti-mouse (Life Technologies)
for 1 hour at room temperature. Slides were counterstained with
0.1 μg/ml 4′,6-diamidino-2-phenylindole (DAPI; Sigma) and cover-
slipped (Vector Laboratories, Burlington, Ontario), and imaging of cell
nuclei was done using a Z1 microscope (Zeiss).
Cell Cycle Analysis by Fluorescent-Activated Cell Sorting
For cell cycle fluorescent-activated cell sorting (FACS) analysis, 2 ×
106 cells were exposed to 2 mM MMS for 30 minutes at 37°C and
Figure 2. (A and E) Representative immunoblots and (B and F) densitometric analysis of induction time kinetics for pCHK1Ser296 and
pATRSer428 in UTC8505-HMGA2 and mock plus/minus MMS treatment. For recovery time kinetics, HMGA2 and mock transfectants were
initially exposed to MMS for 30 minutes, and then cells were washed and cultured in normal culture medium without MMS. At the
indicated time points, immunoreactive pCHK1Ser296 and pATRSer428 were determined. (C and G) Representative Western blots and
(D and H) densitometric analysis done from three independent sets of experiments are shown. (I) Schematic and Western blot showing
the down-regulation of HMGA2 upon doxycycline (doxy) treatment in human fibrosarcoma (C1) cells with doxy-inducible shHMGA2
construct. (J) Recovery time kinetics for pCHK1Ser296 performed in C1 cells in the presence (HMGA2low) and absence of doxy
(HMGA2+). (K and M) Representative immunoblots and (L and N) densitometric analysis of induction time kinetics and recovery time
kinetics for pATRSer428 in C1 cells in the presence (HMGA2low) and absence of doxy (HMGA2+) plus/minus MMS treatment. The pres-
ence of HMGA2 coincided with increased and prolonged pATRSer428 and pCHK1Ser296 levels. *P < .05, **P < .01, and ***P < .001. 0−,
no MMS; 0+, MMS-treated but no recovery time.
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allowed to recover for 0, 1, 2, 4, 6, and 24 hours before being harvested
and fixed in 70% ethanol at 4°C overnight. Cells were washed with
ice-cold PBS followed by treatment with 1 μg/ml RNAse for 2 hours at
37°C. One hour before FACS, cells were stained with 10 μg/ml propi-
dium iodide (Sigma). Cell cycle profiles were obtained with aMoFloXDP
flow cytometer (Beckman Coulter, Mississauga, Ontario) using Summit
5.2 software.
RNA Silencing
Cells (105 cells/well) in six-well plates were cultured overnight and
transfected with 100 nM HMGA2 siRNA (Sigma), 50 nM CHK1
siRNA, and 50 nM scrambled control siRNA (Cell Signaling Tech-
nology) using siLentFect lipid reagent (Bio-Rad, Ontario, Canada).
Protein lysates were collected at 24, 48, and 72 hours and protein levels
of HMGA2 and CHK1 were assessed by Western blot. Immuno-
detection of human CHK2 was performed on lysates of siCHK1-
treated cells to demonstrate the specificity of the CHK1 knockdown.
Caspase 3/7 and Metabolic Activity Assays
Cells were seeded at 7 × 103 cells/well in 96-well plates and
grown overnight before siRNA knockdown of HMGA2 and/or
CHK1 for 24 hours. Thereafter, cells were subjected to MMS treat-
ment for 30 minutes followed by 24- and 48-hour recovery periods.
Caspase-Glo 3/7 (Promega, Madison, WI) and WST assays (Roche
Diagnostics, Laval, Quebec) were performed according to the manufac-
turer’s protocol to determine the percentage of apoptotic and metabol-
ically active cells, respectively, using a 96-well plate reader (Perkin
Elmer, Woodbridge, Ontario).
Fluorescent Detection of Active Caspase 3/7
Qualitative detection of apoptosis through active caspase 3/7 on live
cells was performed using Fluorescent Labeled Inhibitor of Caspases
(FLICA) Apoptosis Detection Kit (Immunocytochemistry Technologies,
Bloomington,MN).Untreated and doxycycline-treatedC1 fibrosarcoma
cells were grown on poly-D-lysine–coated eight-chamber culture slides
Figure 2. (continued).
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(BD Biosciences, Mississauga, Ontario) and transfected with CHK1 siRNA
followedbyMMS treatment and24-hour recovery.The carboxyfluorescein-
labeled (FAM-DEVD-FMK) FLICA probe that covalently binds to
active caspases 3 and 7 was added to the cells and incubated for 1 hour
at 37°C under 5% CO2. Cells were then counterstained with Hoechst
33342 and fluorescence was analyzed with a Z1 microscope (Zeiss).
Co-immunoprecipitation
Protein extraction and co-immunoprecipitation (Co-IP) were per-
formed as described previously [40]. Briefly, cells (treated and control)
were washed with 1× PBS, scraped, and collected by centrifugation. PBS
was discarded and the cell pellet was resuspended in two volumes of lysis
buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM sodium chlo-
ride, 25 mM sodium fluoride, 0.1 mM sodium orthovanadate, 0.2%
Triton X-100, 0.3% NP-40, and protease inhibitors. Protein extracts
were collected by incubation on ice for 30 minutes followed by centri-
fugation at 20,800g for 30 minutes. For IP, 1 mg of protein was mixed
with 2 μg of anti-ATR goat polyclonal antibody (Santa Cruz Bio-
technology) and left rotating at 4°C for 4 hours. The antigen-antibody
mixture was then incubated with a 1:1 mixture of protein A-sepharose
Figure 2. (continued).
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slurry (GEHealthcare Life Sciences, Baie-D’Urfé, Quebec) and protein
G-agarose (Roche Diagnostics) beads for 16 hours at 4°C. The
complexes were washed four times with lysis buffer and the immuno-
precipitates were eluted using sodium dodecyl sulfate elution buffer.
Statistical Analysis
All the experiments were performed at least in triplicate. Repeated
measures two-way analysis of variance (mixed model) and Bonferroni
posttests were performed to determine significance of the grouped
Figure 2. (continued).
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Figure 2. (continued).
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analyses. For all tests, P < .05 was considered as statistically signifi-
cant. Error bars represent the standard deviation of the mean.
Results
Characterization of UTC8505-HMGA2 Transfectants
We generated stable HMGA2 transfectants of UTC8505 (Fig-
ure 1A ) and used previously established A549-HMGA2 human
lung carcinoma cell transfectants [5]. UTC8505-HMGA2 clones 4
and 12 expressed HMGA2 and showed exclusive nuclear expression
of immunoreactive HMGA2 as determined by Western blot analysis
and immunofluorescence (Figure 1, A and B). In all cell models stud-
ied, we confirmed MMS-mediated induction of DNA strand breaks
by detection of γ-H2AX foci at DNA-damaged sites as demonstrated
for UTC8505 transfectants as a representative cell model in Figure 1C .
Employing comet assays, we had previously shown a reduced tail
moment upon MMS treatment in A549 clones expressing HMGA2
[5]. MMS treatment and subsequent comet assays also resulted in a
significantly smaller tail moment with UTC8505-HMGA2 trans-
fectants compared to mock cells (Figure 1D), thus confirming the
protective function of HMGA2 against induced DNA damage.
HMGA2 Causes Sustained Phosphorylation of ATR and
Downstream Target CHK1
We wanted to identify if the DNA protective role of HMGA2
extended to the ATR-CHK1 DNA damage signaling pathway. In
induction time kinetics, UTC8505-HMGA2 (Figure 2, A and B),
A549-HMGA2 (Figure W1A), and corresponding mock were exposed
to 2 mM and 5 mM MMS, respectively, for 0, 2, 5, 10, 15, 20, and
30 minutes. Immunoblot analysis of the protein extracts collected at
these time points showed a gradual increase in the level of pCHK1S296
over time with a maximal phosphorylation at 30 minutes. The level of
pCHK1S296 in response to MMS treatment was significantly increased
in the presence of HMGA2 (Figures 2, A and B, and W1A). Next, we
performed recovery experiments by inducingDNAdamage inHMGA2
and mock transfectants of UTC8505 and A549 for 30 minutes,
followed by a recovery period in fresh culture medium without
MMS. Western blot analysis of pCHK1S296 in protein lysates collected
at 0, 1, 2, 4, 6, and 24 hours of recovery time revealed a gradual
dephosphorylation of activated CHK1 to baseline values after 4 hours
in mock (Figure 2, C andD). By contrast, we observed sustained high-
level presence of pCHK1S296 even at 24 hours of recovery in the pres-
ence of HMGA2 (Figure 2, C and D). We confirmed the presence of
activated upstream CHK1 regulator pATRSer428 uponMMS treatment
Figure 3. Sustained presence of pCHK1Ser296 prolonged G2/M arrest in HMGA2+ cancer cells. (A and B) Cell cycle profiling by FACS
done at 0- and 24-hour recovery periods from MMS treatment in UTC8505-HMGA2 (A) and mock (B) cells. See Figure W2, A and B, for
cell cycle distribution at 1-, 2-, 4-, and 6-hour recovery periods from MMS. Untreated cells were used as control.
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in UTC8505 cells (Figure 2, E–H ). Similar recovery results for
pCHK1S296 were obtained for A549-HMGA2 and mock transfectants,
but recovery data were less pronounced in A549 cells (Figure W1B).
To determine if the presence of endogenous HMGA2 was re-
quired for sustained phosphorylation of CHK1, we employed the
HMGA2+ human fibrosarcoma cell line C1 with doxycycline-
inducible short hairpin (sh) HMGA2 expression for the suppression
of HMGA2 (Figure 2I ). Similar to the other two human cancer cell
models tested, C1 cells showed sustained presence of pCHK1S296 at
24-hour recovery after 0.6 mMMMS treatment. HMGA2 suppression
resulted in a gradual decrease of pCHK1S296 levels, suggesting that the
prolonged CHK1 phosphorylation was at least in part dependent on
the presence of HMGA2 (Figure 2J ). We confirmed the presence of
activated upstream CHK1 regulator pATRSer428 upon MMS treatment
in C1 cells (Figure 2, K –N ). Total CHK1 levels remained unchanged
throughout the recovery period in both HMGA2+ and HMGA2low
conditions (data not shown).
Sustained CHK1 Phosphorylation in the Presence of
HMGA2 Prolongs G2/M Arrest
DNA insult created by genotoxicants activates DNA damage sig-
naling pathways, which arrest the cell cycle to facilitate damage repair
and/or trigger apoptotic death of irreparably damaged cells [41].
CHK1 phosphorylation prevents mitotic entry by inducing G2/M ar-
rest and eliminates cells with impaired DNA [41–43]. We performed
FACS analysis to determine the effect of sustained phosphorylation
Figure 4. (A) Immunoblot detection upon silencing of CHK1 by CHK1siRNA in UTC8505-HMGA2 and mock. CHK1 silencing was specific
and did not affect expression of CHK2 protein. A non-silencing randomized sequence was used as a control in the siRNA experiments
and equal loading of protein lysates was confirmed with β-actin. (B) Higher activation of caspase 3/7 and (C) suppression of metabolic
activity upon CHK1 knockdown at 48 hours of recovery in HMGA2 and mock transfectants. There was no significant difference between
the no siRNA and control siRNA-treated cells with respect to both caspase 3/7 activity and metabolic activity. *P < .05, **P < .01, and
***P < .001.
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of CHK1 on cell cycle distribution. After exposure to 2 mMMMS for
30 minutes, UTC8505-HMGA2 and mock were cultured in normal
medium for 1, 2, 4, 6, and 24 hours before FACS analysis. Cells not
exposed to MMS were used as controls. FACS cell cycle profiles re-
vealed a gradual transition from G1/S to G2/M phase in both mock
and HMGA2 transfectants during the recovery period from 1 to
24 hours. At all recovery time points investigated, HMGA2+ cells
displayed increased accumulation of cells in G2/M phase in compari-
son with mock controls (Figure W2, A and B). At 24-hour recovery,
only 17% of the HMGA2+ cells were in G1 and 55% were arrested in
G2/M, while in mock 38% of cells were in G1 and 43% were found in
G2/M (Figure 3, A and B). An additional subpopulation of HMGA2+
Figure 5. (A) Immunoblots showing successful single knockdown of HMGA2 or CHK1 and double knockdown of HMGA2 and CHK1 in
RD cells as well as (D) specific siRNA-mediated CHK1 silencing in C1 cells. (B and E) Luminescent detection of caspase 3/7 activity after
HMGA2 or CHK1 single knockdown and HMGA2/CHK1 double knockdown at 48 hours of recovery in RD (B) and C1 cells (E). (G) Fluo-
rescent detection of caspase 3/7 activity in CHK1-depleted C1 cells in the presence (HMGA2low) and absence of doxy (HMGA2+) fol-
lowed by MMS treatment and 24-hour recovery. Cells were labeled with caspase 3/7 substrate FLICA (FAM-DEVD-VMK) for fluorescent
detection of apoptotic cells (green). Nuclear staining by Hoechst 33342 revealed nuclear morphology (blue). (C and F) Corresponding
WST assays showed a reduction in metabolic activity upon HMGA2 or CHK1 single knockdown and HMGA2/CHK1 double knockdown in
RD (C) and C1 cells (F). *P < .05, **P < .01, and ***P < .001.
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cells with double the normal DNA content and comprising 11% of
total HMGA2 transfectants was detected at 24-hour recovery (Fig-
ure 3A). Prolonged G2/M arrest in HMGA2 transfectants coincided
with the prolonged presence of pCHK1S296 even after 24 hours of
recovery (Figure 2, C and D). By contrast, in mock the G2/M transi-
tion and the presence of 38% of cells in G1 (Figure 3B) coincided with
low levels of pCHK1S296 observed at 24 hours of recovery (Figure 2,
C and D).
HMGA2-Mediated Enhanced CHK1 Signaling
Inhibits Apoptosis
To test the hypothesis that HMGA2 facilitates the DNA repair
process by increasing activated pCHK1S296 and arresting the cell
cycle as well as preventing apoptosis, we performed siCHK1-specific
knockdown experiments. Upon siCHK1 treatment, Western blot
confirmed a significant, specific, and sustained down-regulation of
CHK1, whereas cellular CHK2 levels remained unchanged in the
HMGA2 or mock transfectants of UTC8505 (Figure 4A ) and
A549 (Figure W4A ). Caspase 3/7 activity increased upon siCHK1
knockdown and was enhanced further upon MMS treatment at
48-hour recovery. By contrast, in the presence of CHK1, caspase
3/7 activity was markedly reduced in both the UTC8505 and the
A549 cell models studied at 24 hours (Figures W3A and W4B ) and
48 hours (Figures 4B and W4C ). Metabolic activity decreases in
cells undergoing apoptosis [44]. CHK1 knockdown followed by
30 minutes of MMS treatment and consecutive recovery for
24 hours (Figures W3B and W4D) and 48 hours (Figures 4C and
Figure 5. (continued).
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W4E ) revealed a decrease in the metabolic activity in UTC8505 and
A549 HMGA2 and mock transfectants, supporting a role for CHK1
in cell survival. The combined CHK1 knockdown and MMS treat-
ment caused an even higher reduction in metabolic activity at 48-hour
recovery. Thus, sustained activation of the DDR signaling factor
pCHK1S296 on an HMGA2+ background caused increased chemo-
resistance of these cancer cells to the DNA-damaging agent MMS.
Abrogation of HMGA2 along with CHK1 Leads to a
Robust Increase in Apoptosis
Depletion of HMGA2 enhances the sensitivity of cancer cells to
certain DNA-damaging agents due to an impairment in DNA re-
pair capacity [37]. In light of this, we decided to examine the effects
of the combined down-regulation of cellular HMGA2 and CHK1.
We employed the endogenous HMGA2-producing RD cells and
C1 fibrosarcoma stable transfectants with doxycycline-inducible
shHMGA2-mediated HMGA2 silencing. RD cells were subjected to
siHMGA2 or siCHK1 single knockdown and combined siHMGA2/
siCHK1 double knockdown (Figure 5A). Upon siRNA treatment,
cells were treated with 1.5 mM MMS and caspase 3/7 and metabolic
activity were measured at 24 hours (Figure W5, A and B) and 48 hours
of recovery time (Figure 5, B and C ). A significant increase in caspase
3/7–mediated apoptosis was observed upon siHMGA2 and siCHK1
single knockdown compared to cells treated with control siRNA (P <
.001). A further robust increase in apoptosis of RD cells was observed
in siHMGA2/siCHK1 double knockdown combined with MMS
treatment at 48-hour recovery (Figure 5B). In agreement with these
findings, suppression of HMGA2 in C1 cells increased the caspase 3/
7–mediated apoptosis and this was enhanced dramatically with the
additional siCHK1 knockdown (Figures 5, D and E , and W5C ).
Our caspase 3/7 fluorescent detection assays in living cells confirmed
the luminometric caspase 3/7 quantitation and revealed changes in
cell and nuclear morphology indicative of apoptosis that included
membrane blebbing and DNA condensation at 24-hour recovery
in cells with reduced HMGA2 levels (Figure 5G ). Similar findings
were observed upon MMS treatment of doxycycline-treated C1 cells
(HMGA2low) and CHK1-depleted cells. The marked decrease in cell
vitality observed upon single and double HMGA2/CHK1 knockdown
corroborated with the observed increase in apoptosis in both the RD
and C1 fibrosarcoma cell models (Figure 5, C and F ; for 24-hour
recovery, see Figure W5, B and D). Altogether, these results implied
that the antiapoptotic action of HMGA2+ cells is augmented by acti-
vated CHK1 and, together with the induction of a mitotic block,
may support the DNA repair function of HMGA2 in cancer cells.
Enhanced Apoptosis upon HMGA2 and CHK1 Knockdown
Extends to Other DNA-Damaging Agents
We also investigated the effect of the genotoxicant and clinical
chemotherapeutic agent HU on the protective role of HMGA2 in
our cancer cell models. HMGA2 and CHK1-deficient C1 fibrosarcoma
cells grown in 96-well plates were treated with 5 mMHU for 24 hours
and left to recover for 4 and 6 hours. The level of active caspase 3/7 was
significantly higher inHU-treated CHK1-deficient C1 cells (Figure 6A;
for 4-hour recovery, see Figure W6A). The combined HMGA2 and
CHK1 knockdown further enhanced cell death and an additional
HU treatment resulted in a robust apoptotic response (more than
two-fold increase) at the 6-hour recovery time point (Figure 6A ).
Similar to MMS treatment and coinciding with the increase in apop-
tosis, we observed markedly decreased metabolic cell activity (more than
two-fold decrease) at the 6-hour recovery time point in HU-treated
HMGA2/CHK1-depleted cells (Figure 6B; for 4-hour recovery, see
Figure W6B). Thus, both HMGA2 and CHK1 acted in concert to
protect tumor cells from genotoxicants by preventing these cells from
entering the apoptotic program.
Figure 5. (continued).
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HMGA2 Interacts with ATR and CHK1
We performed Co-IP studies to investigate possible mechanistic
interactions between HMGA2 and the ATR-CHK1 pathway. We
found that HMGA2 and CHK1 co-immunoprecipitated with
ATR in both endogenous HMGA2-producing C1 human fibro-
sarcoma (Figure 7A ) and in HMGA2 overexpressing UTC8505
transfectants (Figure 7C ). This ATR interactionwithHMGA2 involved
the participation of pATRSer428 and pCHK1S296 and, upon MMS
exposure of UTC8505-HMGA2 transfectants, resulted in a marked
increase in the recruitment of total ATR and pATRSer428. Intriguingly,
DNAse digest before IP did not affect the interaction between
HMGA2 and ATR-CHK1, indicating that chromatin was not required
for this protein complex formation (Figure 7, A and B). However,
HMGA2 was not essential for the interaction of ATR with CHK1 as
demonstrated for HMGA2-negative UTC8505 mock cells (Figure 7C ).
Thus, in an HMGA2+ cellular context, the presence of HMGA2 in the
ATR-CHK1 complex aided in the survival of stem cells and cancer cells.
Discussion
Here, we have demonstrated that HMGA2 exerts a marked cell pro-
tective function against DNA insult through the activation of the
ATR-CHK1 pathway. HMGA2 overexpression is known to be asso-
ciated with many malignant tumors [13] and linked to poor progno-
sis and metastasis [45,46]. Gene expression profiling of 30 cancer
cell lines revealed that HMGA2 contributes to resistance against 4 of
the 11 drugs tested [47]. However, this phenotype may be even more
widespread because HMGA2 is found to be associated with rare tumor-
inducing cells [21].
We recently demonstrated that HMGA1 and HMGA2 can be
linked to the base excision repair machinery and significantly protect
tumor cells against damaging chemical modifications to single DNA
bases due to chemotherapeutic insult [5]. In the present study, we
extended these findings to the protective function of HMGA2 in
human UTC cells and demonstrated the superior ability of HMGA2-
overexpressing UTC to repair MMS-induced DNA damage, suggesting
that the protective role of HMGA2 extends to a broad range of different
cancer cells. Further, the presence of HMGA2 resulted in significant
and sustained hyperphosphorylation of ATR and CHK1 at residues
Ser428 and Ser296, respectively, upon induction of DNA strand breaks
by MMS. This finding is supporting the previous observation that
HMGA2 is responsible for the hyperphosphorylation and prolonged
phosphorylation of the DNA-dependent protein kinase catalytic
subunit (DNA-PKc, another phosphatidylinositol 3-kinase-related
kinase member) at Thr2609 and Ser2056 upon induction of DNA insult
by doxorubicin [48]. The ability of HMGA2 to facilitate hyper-
phosphorylation of DNA-PKc and ATR-CHK1 kinases may reflect
yet another strategy employed by HMGA2+ tumor cells to resist
DNA-damaging agents, with HMGA2 capitalizing on the known co-
operation of DNA-PKc with ATM and ATR pathways to phosphory-
late the checkpoint-related proteins [49]. In fission yeast, sustained
phosphorylation of CHK1 is maintained by the interaction between
pCHK1S345 and either 14-3-3 [50,51] or Crb2 [52] proteins, which
protect the phosphorylation status of CHK1 [53]. While HMGA2
was not essential for ATR-CHK1 interaction in our human cancer cell
models, increased and sustained ATR and CHK1 phosphorylation
was dependent on the presence of HMGA2, suggesting a novel role
for HMGA2 in modulating the activity status of the ATR-CHK1
signaling complex.
CHK1 is a potential target for anticancer therapy and many CHK1-
selective inhibitors are in various stages of clinical trials [54–56]. CHK1
plays important roles in cell cycle arrest, non-homologous end join-
ing [57], and homologous recombination repair mechanisms [30].
Figure 6. HU treatment caused (A) caspase 3/7 activation and (B) reduced metabolic activity at 6 hours of recovery in CHK1-deficient C1
cells. All experiments were done in the presence (HMGA2low) and absence of doxy (HMGA2+). *P < .05, **P < .01, and ***P < .001.
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Figure 7. Co-IP revealing the interaction of HMGA2 with ATR and CHK1 in (A) C1 human fibrosarcoma cells and (C) UTC8505 cells.
HMGA2 and CHK1 were co-immunoprecipitated with affinity-purified anti-ATR goat polyclonal antibody. This protein-protein interaction
was found to be DNA independent and observed (B) after cleavage of DNA with 5 μg/ml of DNAse. Normal goat IgG was used as
negative control. (D) Proposed model for the protective mechanism of HMGA2 against genotoxicants in cancer cells. Upon genotoxic
insult, HMGA2 engages in a complex with pATR-pCHK1 and increases and prolongs ATR-CHK1 phosphorylation status. This prolongs
G2/M arrest, facilitates DNA damage repair, and increases survival and chemoresistance of cancer cells.
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Phosphorylation-dependent activation of CHK1 is essential for reg-
ulating cell cycle delay and cell survival [58]. We hypothesized that
the MMS-induced sustained accumulation of pCHK1S296 in the
presence of HMGA2 may prolong the cell cycle arrest to facilitate
effective DNA repair and prevent premature entry into mitosis result-
ing in apoptosis. Mitotic arrest at the G2/M checkpoint remains active
until completion of DNA repair and is controlled and regulated by
CHK1 [42,59–62]. In Saccharomyces pombe, sustained CHK1 phos-
phorylation is essential in maintaining the G2 DNA damage checkpoint
to prevent the entry of damaged cells into mitosis [53]. We identified
the persistent presence of pCHK1S296 in the presence of HMGA2 to
be accompanied by a prolonged G2/M arrest. Thus, HMGA2 appeared
to confer in tumor cells the capacity for timely repair of DNA lesions
and this was facilitated by a CHK1-mediated cell cycle delay.
We asked if the increased activation of CHK1 signaling and
mitotic arrest observed in HMGA2 clones can promote cell survival
by exerting an antiapoptotic effect. The siRNA-mediated knockdown
of CHK1 in HMGA2+ cancer cells resulted in caspase 3/7–mediated
apoptotic cell death and this apoptotic response was further amplified
in the presence of DNA-damaging agents MMS and HU in all
HMGA2+ cell models studied. These results are consistent with the
previous findings that CHK1 inhibitors enhance the cytotoxicity
induced by DNA-damaging agents [42,62] and the role of the ATR-
CHK1 pathway activation in preventing caspase 3–mediated apoptosis
in response to ionizing radiation (IR)- or UV-induced DNA damage
[63,64]. Furthermore, the combined knockdown of both HMGA2
and CHK1, in our fibrosarcoma model of shHMGA2-regulated sup-
pression of HMGA2, significantly increased caspase 3/7 activity and
cytotoxicity. Again, this effect was further augmented by the addition
of DNA-damaging agents. This increase in apoptosis coincided with a
marked decrease in cell viability, a finding consistent with recent reports
demonstrating increased sensitivity of cancer cells to both radiothera-
peutics and chemotherapeutics upon depletion of HMGA2 [5,37,65].
HMGA2 gene silencing had been reported to upregulate apoptosis
in well-differentiatedliposarcomas overexpressing HMGA2 and in
serous ovarian carcinomas [66,67]. Here, we identified HMGA2 as
a novel interaction partner of ATR-CHK1 complex in cancer cells.
This interaction involved phosphorylated ATR/CHK1 but was inde-
pendent of the presence of DNA. It is tempting to speculate that the
increased and extended phosphorylation status of ATR and CHK1 in
the presence of HMGA2 reflects a new function of HMGA2 aimed at
extending the activity of this pathway. This involved a prolonged cell
cycle arrest to provide sufficient time for DNA damage repair and pre-
vent cancer cell apoptosis. Importantly, formation of a functional
ATR-CHK1 complex was readily observed in cancer cells devoid of
HMGA2. However, cancer cells low in or devoid of HMGA2 failed
to respond with prolonged phosphorylation of ATR and CHK1 and
more easily succumbed to cell death when exposed to genotoxicants.
We summarized these findings in a proposed model (Figure 7D). In
the presence of the genotoxic agents MMS and HU, HMGA2
through interaction with the ATR-CHK1 complex, facilitated sus-
tained activation of this DDR pathway and this contributed to an in-
crease in chemoresistance in HMGA2-positive cancer cells. What
could be the possible underlying mechanisms? CHK1 phosphoryla-
tion requires ATR phosphorylation and this is a highly regulated pro-
cess [68]. At ssDNA-damaged sites, ATR interacts with the 9-1-1
complex (Rad9-Rad1-Hus1) and pTOPBP1 and the latter is neces-
sary for ATR activation [69–71]. ATM-mediated phosphorylation
of TOPBP1 can also enhance ATR phosphorylation [72]. Acting as
a linker protein, HMGA2 at damaged DNA sites may increase the
local concentration of 9-1-1 complex, TOPBP1, and ATR, resulting
in sustained ATR phosphorylation through physical proximity be-
tween activated TOPBP1 and its ATR substrate. HMGA2 may also
facilitate ATM-dependent ATR activation [72]. HMGA2 and ATM
are known to interact and this results in increased pATM levels [37].
ATM kinase activity enhances phosphorylation of TOPBP1, which,
in turn, promotes ATR phosphorylation. Thus, HMGA2 may act as a
novel link between ATM activation and prolonged phosphorylation
of ATR in HMGA2+ cells. Finally, we cannot exclude that the pos-
sible recruitment of HMGA2 to a preformed pATR-CHK1 complex
can block ATR and CHK1 phosphorylated sites from phosphatase
attack, thus preventing pATR and/or pCHK1 from reverting into
their inactive non-phosphorylated forms.
Conventional chemotherapies often fail primarily due to the devel-
opment of multidrug chemoresistance and this appears to be in part a
function of cancer-initiating cells (CICs) [73]. The re-expression of
HMGA2 in cancer cells as opposed to their non-malignant counter-
parts promotes both chemoresistance and genomic stability through
survival-promoting ATR-CHK1 activation and enhanced DDR. It is
tempting to suggest a protective role for HMGA2 in cancer cell sub-
sets with stem-like properties [21], and this has important clinical
relevance, as tumor recurrence may be attributed to the presence
of an HMGA2-positive CIC pool. Our data identify HMGA2 as
an important contributor to chemoresistance through ATR-CHK1
signaling in HMGA2-expressing cancers and warrant the develop-
ment of small inhibitors that target both the chromatin-binding
property of HMGA2 and the ATR-CHK1 pathway to effectively
bypass the antiapoptotic actions of HMGA2 and ATR/CHK1. The
ability to block these mechanisms of chemoresistance in HMGA2-
expressing cancer cells will likely also target and possibly incapacitate
the CIC pool, thereby providing a marked advance in the treatment
of some chemoresistant and aggressive HMGA2+ cancer types.
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Figure W1. (A) Densitometric analysis of induction time kinetics to
demonstrate immunoreactive pCHK1Ser296 in A549-HMGA2 and
mock transfectants upon MMS treatment. (B) Densitometric rep-
resentation of Western blots of pCHK1Se296 after 30 minutes of
MMS treatment and recovery time kinetics performed at the indi-
cated time points in A549-HMGA2 and mock. Densitometric anal-
ysis done from three independent sets of experiments is shown.
*P < .05, **P < .01, and ***P < .001.
Figure W2. (A and B) FACS results indicating the percentage distribution of cells in the different phases of cell cycle at 1-, 2-, 4-, and
6-hour recovery periods from MMS treatment in UTC8505 HMGA2 (A) and mock (B) transfectants.
Figure W3. CHK1 knockdown exhibited (A) an increase in caspase 3/7–mediated apoptosis and (B) a decrease in metabolic activity at
24 hours of recovery from MMS treatment in UTC8505-HMGA2 and mock. *P < .05, **P < .01, and ***P < .001.
Figure W4. (A) Representative immunoblot detection of siRNA-mediated CHK1 silencing in A549-HMGA2 and mock. CHK1 silencing
was specific and did not affect expression of CHK2 protein. (B and C) An increased activation of caspase 3/7 and (D and E)
corresponding reduction in metabolic activity upon CHK1 knockdown were observed at 24- and 48-hour recovery periods in A549-
HMGA2 and mock. *P < .05, **P < .01, and ***P < .001.
Figure W5. Suppression of both HMGA2 and CHK1 followed by MMS treatment and 24 hours of recovery displayed (A and C) enhanced
caspase 3/7 activity and (B and D) reduced metabolic activity in RD rhabdomyosarcoma and C1 fibrosarcoma. *P < .05, **P < .01, and
***P < .001.
Figure W6. (A and B) Combined CHK1 knockdown and HU treatment in doxy-treated (HMGA2low) C1 fibrosarcoma cells significantly
coincided with increased caspase 3/7 activity (A) and reduced metabolic activity (B), suggesting activation of caspase 3/7–mediated
apoptosis at 4 hours of recovery from HU. *P < .05, **P < .01, and ***P < .001.
